Biocept Inc (NASDAQ:BIOC) has delivered a dose of good news by announcing that clinical data which supports the use of its CTC liquid biopsy testing platform as an instrument to help in the monitoring and treatment of breast cancer will be presented at this year’s San Antonio Breast Cancer Symposium.
The conference is being held from December 10th through the 14th at the Henry B. Gonzalez convention center in Austin, Texas.
The San Diego company’s poster presentation is entitled Clinical Data in Over 1,500 Patients Across All Stages of Breast Cancer with Target Selector.
The hope is that the presentation of a data set, which evaluates over 1,500 patients, will showcase how Biocept’s Target Selector assays aid doctors in their understanding of treatments for breast cancer patients.
“Our CTC-based liquid biopsy testing offers physicians the ability to assess metastatic disease burden and informative biomarkers to aid clinical decision making in patients with breast cancer,” said Dr. Veena Singh, a senior vice-president and a senior medical director at Biocept.
“Additionally, our liquid biopsy testing affords the ability to contemporaneously monitor an evolving tumor mutation landscape in a cost-effective and minimally invasive manner for disease progression, recurrence, emergence of resistance mechanisms, and identification of potentially actionable therapeutic targets,” Dr. Singh said.
Biocept’s biomarker tests detect and isolate cancer biomarkers such as circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA).
Biocept offers the test commercially to doctors, hospitals, clinics and researchers, with a focus on lung, breast, gastric, colorectal and prostate cancers as well as melanoma.